ArticleWorld journal of oncology2026
TRIM33 Reverses Cisplatin Resistance in Non-Small Cell Lung Cancer by Regulating the PI3K/AKT Pathway via Ubiquitination-Mediated Degradation of LPCAT1.
Article in World journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for 80-85% of cases. Cisplatin (DDP) is a first-line chemotherapy drug for NSCLC, but acquired DDP resistance severely limits therapeutic efficacy. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) is involved in tumor progression, but its role in DDP resistance of NSCLC remains unclear. This study aimed to investigate the regulatory mechanism of LPCAT1 in DDP-resistant NSCLC and explore the potential role of tripartite motif-containing 33 (TRIM33) in modulating LPCAT1. Methods: DDP-resistant NSCLC cell lines (A549/DDP, PC-9/DDP) were established by gradual concentration gradient induction. Cell viability was detected by cell counting kit-8 (CCK-8) assay to determine half-maximal inhibitory concentration (IC Results: LPCAT1 protein expression was significantly upregulated in DDP-resistant NSCLC cells, while mRNA expression showed no significant difference. LPCAT1 overexpression enhanced DDP resistance, activated the PI3K/AKT signaling pathway, and promoted glycolysis in NSCLC cells, whereas LPCAT1 knockdown reversed these effects. TRIM33 expression was negatively correlated with DDP resistance, and TRIM33 directly interacted with LPCAT1 to promote its ubiquitination and degradation via the proteasomal pathway. Overexpression of TRIM33 inhibited the PI3K/AKT pathway and glycolysis, thereby sensitizing DDP-resistant cells to DDP. Conclusion: TRIM33 regulates LPCAT1 stability through ubiquitination-mediated degradation, thereby suppressing PI3K/AKT signaling and glycolysis and attenuating DDP resistance in NSCLC. These findings suggest that the TRIM33-LPCAT1 axis may represent a potential therapeutic candidate for DDP-resistant NSCLC and provide a basis for further investigation of strategies to improve DDP sensitivity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.